A team of researchers at the Cincinnati Children’s Heart Institute used an experimental targeted molecular therapy to block a matrix-forming protein, called fibronectin, in heart cells damaged by heart attack, reducing levels of scarred muscle tissue and saving mouse models from heart failure. Their work appears in the journal Circulation. Left: this image shows fibrotic heart cells from a patient who had heart failure; the cells have an elaborate...
